HoldsUp

FoundMyFitness · 2026-04-06 · Rhonda Patrick (host), Ati Hakim

How Omega-3s May Slow Biological Aging (New Evidence)

52 research-tied claims examined: 2 contradicted 4 overstated 1 context 41 supported 4 unverified

4

Overstated

0:20:21Rhonda Patrick (host)overstatedlow

A 2019 prospective study using the DNA GrimAge clock found that individuals with higher omega-3 intake had slowed age acceleration.

"So, one of the first studies here, this was in 2019, showed that omega-3 does slow biological aging. This was a prospective study looking at people that basically reported their omega-3 intake, and the DNA GrimAge clock was used in this study." (said at 0:20:21)

The 2019 landmark study that developed and validated the DNAm GrimAge epigenetic clock (Lu et al., 2019) evaluated lifestyle and dietary factors in large prospective cohorts (such as the Framingham Heart Study and the Women's Health Initiative). The authors observed that higher self-reported dietary intake of omega-3 polyunsaturated fatty acids and adherence to healthy dietary patterns were inversely associated with GrimAge epigenetic age acceleration (AgeAccelGrim). However, asserting that the study 'showed that omega-3 does slow biological aging' overstates observational and cross-sectional associations from self-reported dietary data, which cannot establish causality.

0:24:57Rhonda Patrick (host)overstatedhigh

In the DO-HEALTH trial, omega-3 supplementation alone reduced infections by 13% and decreased falls by 13%.

"The omega-3 alone without any other, you know, vitamin D or resistance training reduced infections by 13%. And it decreased falls by 13%." (said at 0:24:57)

In the DO-HEALTH randomized controlled trial of 2,157 older adults, the main effect of omega-3 fatty acids (compared with no omega-3) was an 11% relative reduction in the incidence rate of infections (incidence rate ratio [IRR] 0.89, 99% CI 0.78–1.01, p = 0.02; difference in mean change in incidence rate of -0.13), which was not statistically significant under the trial's prespecified threshold of p < 0.01 for multiple primary endpoints. For fall prevention, omega-3 supplementation was associated with a 10% reduction in total falls (IRR 0.90, 95% CI 0.81–1.00, p = 0.04), not 13%. Furthermore, these findings reflect the main effects across the 2x2x2 factorial design rather than an isolated 'omega-3 alone' treatment arm.

0:36:57Rhonda Patrick (host)overstatedlow

High levels of inflammation inhibit the presynaptic release of serotonin.

"When you have high inflammation, it stops the release of serotonin. You're not able to release serotonin from the from the presynapse." (said at 0:36:57)

Inflammatory cytokines modulate central monoaminergic transmission through multiple mechanisms, including depleting the serotonin precursor tryptophan (via indoleamine 2,3-dioxygenase activation), enhancing serotonin transporter (SERT) activity and reuptake, and reducing neurotransmitter availability. However, asserting that high inflammation completely "stops the release of serotonin" or leaves the presynapse unable to release serotonin is an overstatement of the neurochemical evidence, which demonstrates modulation and reduction in serotonergic signaling rather than total cessation of presynaptic exocytosis.

0:58:32Rhonda Patrick (host)overstatedmoderate

Studies show that 1 gram per day of omega-3 is safe in children, lowers ADHD symptoms, and improves cognition.

"And there are studies showing that a gram a day is safe in children and it lowers ADHD. It improves cognition." (said at 0:58:32)

While randomized controlled trials confirm that omega-3 supplementation (around 1 g/day) is safe and well-tolerated in children with no significant increase in adverse effects, the claim that it reliably reduces ADHD and improves cognition overstates the evidence. Meta-analyses of randomized trials show that omega-3 fatty acid supplementation produces only small or modest improvements in ADHD symptom severity compared to standard pharmacological treatments, and some comprehensive systematic reviews (including Cochrane) find no statistically significant difference over placebo. Furthermore, meta-analyses evaluating cognitive performance in children and youth with neurodevelopmental disorders have found no consistent evidence of broader cognitive enhancement beyond minor, selective attention test measures in subgroup analyses.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.